Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
27
GCTK Quote, Financials, Valuation and Earnings
Last price:
$4.17
Seasonality move
:
-7.61%
Day range:
$4.17 - $4.47
52-week range:
$4.17 - $467.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.72x
P/B ratio:
43.73x
Volume:
12.4K
Avg. volume:
50.6K
1-year change:
-98.67%
Market cap:
$120.3M
Revenue:
--
EPS (TTM):
-$1,319.98
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GCTK
GlucoTrack, Inc.
|
-- | -- | -- | -- | -- |
|
CATX
Perspective Therapeutics, Inc.
|
$147K | -$0.35 | -9.65% | -37.91% | $12.3077 |
|
PMI
Picard Medical
|
-- | -- | -- | -- | -- |
|
VNRX
VolitionRX Ltd.
|
$806.3K | -$0.04 | 272.5% | -33.67% | $2.20 |
|
VTAK
Catheter Precision, Inc.
|
$310K | -$0.20 | 118.75% | -11.57% | -- |
|
XTNT
Xtant Medical Holdings, Inc.
|
$28.5M | -- | -2.42% | -100% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GCTK
GlucoTrack, Inc.
|
$4.20 | -- | $120.3M | -- | $0.00 | 0% | 6.72x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.8800 | $12.3077 | $214.1M | -- | $0.00 | 0% | 195.28x |
|
PMI
Picard Medical
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
VNRX
VolitionRX Ltd.
|
$0.25 | $2.20 | $30.7M | -- | $0.00 | 0% | 17.13x |
|
VTAK
Catheter Precision, Inc.
|
$1.68 | -- | $2.1M | 0.40x | $0.00 | 0% | 7.90x |
|
XTNT
Xtant Medical Holdings, Inc.
|
$0.78 | $1.50 | $108.6M | 76.08x | $0.00 | 0% | 0.85x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GCTK
GlucoTrack, Inc.
|
54.52% | 0.855 | 1.75% | 1.49x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.691 | 1.3% | 8.47x |
|
PMI
Picard Medical
|
-- | 0.000 | -- | -- |
|
VNRX
VolitionRX Ltd.
|
-48.16% | 2.566 | 15.4% | 0.04x |
|
VTAK
Catheter Precision, Inc.
|
68.63% | -0.348 | 537.37% | 0.41x |
|
XTNT
Xtant Medical Holdings, Inc.
|
39.2% | 2.955 | 35.76% | 1.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GCTK
GlucoTrack, Inc.
|
-$9K | -$4.3M | -2079.63% | -- | -- | -$4.7M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
PMI
Picard Medical
|
-- | -- | -- | -- | -- | -- |
|
VNRX
VolitionRX Ltd.
|
$318.2K | -$5.1M | -- | -- | -813.17% | -$3.5M |
|
VTAK
Catheter Precision, Inc.
|
-$320K | -$3M | -79.27% | -192.05% | -1336.73% | -$2.2M |
|
XTNT
Xtant Medical Holdings, Inc.
|
$22M | $2.5M | 2.15% | 3.78% | 7.64% | $4.2M |
GlucoTrack, Inc. vs. Competitors
-
Which has Higher Returns GCTK or CATX?
Perspective Therapeutics, Inc. has a net margin of -- compared to GlucoTrack, Inc.'s net margin of -12425.36%. GlucoTrack, Inc.'s return on equity of -- beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital GCTKGlucoTrack, Inc.-- -$4.64 $6M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About GCTK or CATX?
GlucoTrack, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 327.35%. Given that Perspective Therapeutics, Inc. has higher upside potential than GlucoTrack, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than GlucoTrack, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GCTKGlucoTrack, Inc.0 0 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is GCTK or CATX More Risky?
GlucoTrack, Inc. has a beta of 0.300, which suggesting that the stock is 70.003% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.
-
Which is a Better Dividend Stock GCTK or CATX?
GlucoTrack, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GlucoTrack, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GCTK or CATX?
GlucoTrack, Inc. quarterly revenues are --, which are smaller than Perspective Therapeutics, Inc. quarterly revenues of $209K. GlucoTrack, Inc.'s net income of -$4.2M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, GlucoTrack, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GlucoTrack, Inc. is 6.72x versus 195.28x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GCTKGlucoTrack, Inc.6.72x -- -- -$4.2M CATXPerspective Therapeutics, Inc.195.28x -- $209K -$26M
-
Which has Higher Returns GCTK or PMI?
Picard Medical has a net margin of -- compared to GlucoTrack, Inc.'s net margin of --. GlucoTrack, Inc.'s return on equity of -- beat Picard Medical's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GCTKGlucoTrack, Inc.-- -$4.64 $6M PMIPicard Medical-- -- -- -
What do Analysts Say About GCTK or PMI?
GlucoTrack, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Picard Medical has an analysts' consensus of -- which suggests that it could fall by --. Given that GlucoTrack, Inc. has higher upside potential than Picard Medical, analysts believe GlucoTrack, Inc. is more attractive than Picard Medical.
Company Buy Ratings Hold Ratings Sell Ratings GCTKGlucoTrack, Inc.0 0 0 PMIPicard Medical0 0 0 -
Is GCTK or PMI More Risky?
GlucoTrack, Inc. has a beta of 0.300, which suggesting that the stock is 70.003% less volatile than S&P 500. In comparison Picard Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock GCTK or PMI?
GlucoTrack, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Picard Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GlucoTrack, Inc. pays -- of its earnings as a dividend. Picard Medical pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GCTK or PMI?
GlucoTrack, Inc. quarterly revenues are --, which are larger than Picard Medical quarterly revenues of --. GlucoTrack, Inc.'s net income of -$4.2M is higher than Picard Medical's net income of --. Notably, GlucoTrack, Inc.'s price-to-earnings ratio is -- while Picard Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GlucoTrack, Inc. is 6.72x versus -- for Picard Medical. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GCTKGlucoTrack, Inc.6.72x -- -- -$4.2M PMIPicard Medical-- -- -- --
-
Which has Higher Returns GCTK or VNRX?
VolitionRX Ltd. has a net margin of -- compared to GlucoTrack, Inc.'s net margin of -862.39%. GlucoTrack, Inc.'s return on equity of -- beat VolitionRX Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GCTKGlucoTrack, Inc.-- -$4.64 $6M VNRXVolitionRX Ltd.50.73% -$0.05 -$24.7M -
What do Analysts Say About GCTK or VNRX?
GlucoTrack, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 780%. Given that VolitionRX Ltd. has higher upside potential than GlucoTrack, Inc., analysts believe VolitionRX Ltd. is more attractive than GlucoTrack, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GCTKGlucoTrack, Inc.0 0 0 VNRXVolitionRX Ltd.4 2 0 -
Is GCTK or VNRX More Risky?
GlucoTrack, Inc. has a beta of 0.300, which suggesting that the stock is 70.003% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.
-
Which is a Better Dividend Stock GCTK or VNRX?
GlucoTrack, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GlucoTrack, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GCTK or VNRX?
GlucoTrack, Inc. quarterly revenues are --, which are smaller than VolitionRX Ltd. quarterly revenues of $627.3K. GlucoTrack, Inc.'s net income of -$4.2M is higher than VolitionRX Ltd.'s net income of -$5.4M. Notably, GlucoTrack, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GlucoTrack, Inc. is 6.72x versus 17.13x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GCTKGlucoTrack, Inc.6.72x -- -- -$4.2M VNRXVolitionRX Ltd.17.13x -- $627.3K -$5.4M
-
Which has Higher Returns GCTK or VTAK?
Catheter Precision, Inc. has a net margin of -- compared to GlucoTrack, Inc.'s net margin of -1037.17%. GlucoTrack, Inc.'s return on equity of -- beat Catheter Precision, Inc.'s return on equity of -192.05%.
Company Gross Margin Earnings Per Share Invested Capital GCTKGlucoTrack, Inc.-- -$4.64 $6M VTAKCatheter Precision, Inc.-141.59% -$1.70 $21.3M -
What do Analysts Say About GCTK or VTAK?
GlucoTrack, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Catheter Precision, Inc. has an analysts' consensus of -- which suggests that it could grow by 2161.97%. Given that Catheter Precision, Inc. has higher upside potential than GlucoTrack, Inc., analysts believe Catheter Precision, Inc. is more attractive than GlucoTrack, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GCTKGlucoTrack, Inc.0 0 0 VTAKCatheter Precision, Inc.0 0 0 -
Is GCTK or VTAK More Risky?
GlucoTrack, Inc. has a beta of 0.300, which suggesting that the stock is 70.003% less volatile than S&P 500. In comparison Catheter Precision, Inc. has a beta of -1.301, suggesting its less volatile than the S&P 500 by 230.084%.
-
Which is a Better Dividend Stock GCTK or VTAK?
GlucoTrack, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GlucoTrack, Inc. pays -- of its earnings as a dividend. Catheter Precision, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GCTK or VTAK?
GlucoTrack, Inc. quarterly revenues are --, which are smaller than Catheter Precision, Inc. quarterly revenues of $226K. GlucoTrack, Inc.'s net income of -$4.2M is lower than Catheter Precision, Inc.'s net income of -$2.3M. Notably, GlucoTrack, Inc.'s price-to-earnings ratio is -- while Catheter Precision, Inc.'s PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GlucoTrack, Inc. is 6.72x versus 7.90x for Catheter Precision, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GCTKGlucoTrack, Inc.6.72x -- -- -$4.2M VTAKCatheter Precision, Inc.7.90x 0.40x $226K -$2.3M
-
Which has Higher Returns GCTK or XTNT?
Xtant Medical Holdings, Inc. has a net margin of -- compared to GlucoTrack, Inc.'s net margin of 3.93%. GlucoTrack, Inc.'s return on equity of -- beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.
Company Gross Margin Earnings Per Share Invested Capital GCTKGlucoTrack, Inc.-- -$4.64 $6M XTNTXtant Medical Holdings, Inc.66.13% $0.01 $82.9M -
What do Analysts Say About GCTK or XTNT?
GlucoTrack, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 93.3%. Given that Xtant Medical Holdings, Inc. has higher upside potential than GlucoTrack, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than GlucoTrack, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GCTKGlucoTrack, Inc.0 0 0 XTNTXtant Medical Holdings, Inc.2 0 0 -
Is GCTK or XTNT More Risky?
GlucoTrack, Inc. has a beta of 0.300, which suggesting that the stock is 70.003% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.
-
Which is a Better Dividend Stock GCTK or XTNT?
GlucoTrack, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GlucoTrack, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GCTK or XTNT?
GlucoTrack, Inc. quarterly revenues are --, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. GlucoTrack, Inc.'s net income of -$4.2M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, GlucoTrack, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 76.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GlucoTrack, Inc. is 6.72x versus 0.85x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GCTKGlucoTrack, Inc.6.72x -- -- -$4.2M XTNTXtant Medical Holdings, Inc.0.85x 76.08x $33.3M $1.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
